G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
G1 Therapeutics, Inc. (GTHX) Tops Q1 EPS by 11c
May 3, 2023 6:36 AM EDTG1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q1 EPS of ($0.53), $0.11 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $12.95 million versus the consensus estimate of $11.17 million.
For earnings history and earnings-related data on G1 Therapeutics, Inc. (GTHX) click here.
... More